NSC 743380 induces apoptosis in sensitive cell lines through activation of tyrosine kinase 2 (Tyk2)

被引：0
|
作者：
Newton, Dianne L. [1 ]
Stockwin, Luke H. [1 ]
Mullendore, Michael E. [1 ]
Han, Bingnan [1 ]
Morrison, Bethanie L. [1 ]
Borgel, Suzanne [2 ]
Stotler, Howard [2 ]
Fang, Bingliang [3 ]
Hollingshead, Melinda G. [4 ]
机构：
[1] NCI, Drug Mech Grp, SAIC Frederick Inc, Frederick, MD 21701 USA
[2] NCI, In Vivo Preclin Support Grp, SAIC Frederick Inc, Frederick, MD 21701 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
[4] NCI, Biol Testing Branch, Frederick, MD 21701 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-2810
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2810
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia
    Sanda, Takaomi
    Tyner, Jeffrey W.
    Gutierrez, Alejandro
    Ngo, Vu N.
    Moriggl, Richard
    Ahn, Yebin
    Glover, Jason M.
    Chang, Bill H.
    Willis, Stephanie G.
    Staudt, Louis M.
    Druker, Brian J.
    Look, A. Thomas
    BLOOD, 2010, 116 (21) : 1298 - 1298
  • [32] EFFICACY OF THE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR TAK-279 IN TWO PRECLINICAL MOUSE MODELS OF COLITIS
    Kong, Kok-Fai
    Khan, Md A. Wadud
    Singh, Namita
    Van Anh Nguyen
    Wilson, Elizabeth
    Tang, Jay
    Marusic, Suzana
    Xia, Guliang
    Petrakis, Ioannis
    Nguyen, Deborah G.
    GASTROENTEROLOGY, 2024, 166 (05) : S1399 - S1399
  • [33] Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes
    Potla, Ramesh
    Koeck, Thomas
    Wegrzyn, Joanna
    Cherukuri, Srujana
    Shimoda, Kazuya
    Baker, Darren P.
    Wolfman, Janice
    Planchon, Sarah M.
    Esposito, Christine
    Hoit, Brian
    Dulak, Jozef
    Wolfman, Alan
    Stuehr, Dennis
    Larner, Andrew C.
    MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (22) : 8562 - 8571
  • [34] Efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor TAK-279 in two preclinical mouse models of colitis
    Kong, K. F.
    Khan, M. A. W.
    Singh, N.
    Nguyen, V. A.
    Wilson, E.
    Tang, J.
    Marusic, S.
    Xia, G.
    Petrakis, I.
    Nguyen, D. G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I437 - I438
  • [35] Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
    Wrobleski, Stephen T.
    Moslin, Ryan
    Lin, Shuqun
    Zhang, Yanlei
    Spergel, Steven
    Kempson, James
    Tokarski, John S.
    Strnad, Joann
    Zupa-Fernandez, Adriana
    Cheng, Lihong
    Shuster, David
    Gillooly, Kathleen
    Yang, Xiaoxia
    Heimrich, Elizabeth
    McIntyre, Kim W.
    Chaudhry, Charu
    Khan, Javed
    Ruzanov, Max
    Tredup, Jeffrey
    Mulligan, Dawn
    Xie, Dianlin
    Sun, Huadong
    Huang, Christine
    D'Arienzo, Celia
    Aranibar, Nelly
    Chiney, Manoj
    Chimalakonda, Anjaneya
    Pitts, William J.
    Lombardo, Louis
    Carter, Percy H.
    Burke, James R.
    Weinstein, David S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 8973 - 8995
  • [36] Janus kinase 2 activation by the platelet-activating factor receptor (PAFR):: Roles of Tyk2 and PAFR C terminus
    Lukashova, V
    Chen, ZG
    Duhé, RJ
    Rola-Pleszezynski, M
    Stanková, J
    JOURNAL OF IMMUNOLOGY, 2003, 171 (07): : 3794 - 3800
  • [37] Tyrosine kinase 2 (Tyk2) interacts with and phosphorylates Siva-1, and auguments the apoptotic effect induced by Siva-1.
    Kakumitsu, Haruko
    Shimoda, Kazuya
    Haro, Takashi
    Shide, Kotaro
    Kumano, Takashi
    Oku, Seido
    Kamezaki, Kenjirou
    Numata, Akihiko
    Takenaka, Katsuto
    Harada, Mine
    BLOOD, 2006, 108 (11) : 490A - 490A
  • [38] BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, does not affect the pharmacokinetics of methotrexate in healthy subjects
    Chimalakonda, A.
    Jones, J., III
    Dockens, R.
    Throup, J.
    Banerjee, S.
    Girgis, I.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S437 - S438
  • [39] Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase
    Gauzzi, MC
    Velazquez, L
    McKendry, R
    Mogensen, KE
    Fellous, M
    Pellegrini, S
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (34) : 20494 - 20500
  • [40] BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS
    Fitzgerald, O.
    Gladman, D. D.
    Mease, P. J.
    Ritchlin, C. T.
    Smolen, J. S.
    Gao, L.
    Hu, S.
    Nowak, M.
    Banerjee, S.
    Catlett, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 215 - 216
12345